ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study

Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X, about recent paper published in Lung Cancer Journal:

“ES-SCLC (Extensive Stage Small Cell Lung Cancer)

• 5-year survival outcomes inIMpower133 and
  IMbrella a extension study.
• 5-year OS rate 12% “

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella a extension study

Authors: Martin Reck, Rafal Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian Hochmair, Florian Huemer, Gilberto de Castro, Libor Havel, Reyes Bernabé Caro, György Losonczy, Jong-Seok Lee, Dariusz M. Kowalski, Zoran Andric, Raffaele Califano, Andrea Veatch, Gregory Gerstner, Marta Batus, Stefanie Morris, Monika Kaul, Vaikunth Cuchelkar, Huafei Li, Bradford J. Danner, Barzin Y. Nabet and Stephen V. Liu

Source: Katsuaki Maehara/X